{"schema_version":"1.0","type":"article","title":"降解藥全景：首個PROTAC乳癌藥上市，亞洲接棒","url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.md","lang":"zh-Hant","date":"2026-11-10","publish_at":"2026-11-10T15:34:20+08:00","updated_at":"2026-11-10","category":"商業分析系列","topic":"商業分析系列","tags":["蛋白降解","PROTAC","Veppanu","BeOne tacabrutideg","Astellas setidegrasib","安宏 AH-001","開拓藥業 GT20029"],"summary":"BeOne 11 月 5 日宣布 BTK 降解藥 tacabrutideg 樞紐二期達標、2027 年年中送件；全球第一個上市的 PROTAC Veppanu 第三季卻只帶給 Arvinas 50 萬美元權利金。Astellas 的 KRAS G12D 降解藥已進三期，台灣安宏走外用雄性禿路線，最近的對手是開拓藥業。","key_points":["Veppanu（vepdegestrant）於 2026-05-01 獲 FDA 核准，是第一個上市的 PROTAC；Arvinas 2026 年第三季營收僅 50 萬美元，全為 Rigel 權利金。","BeOne 於 2026-11-05 宣布 tacabrutideg 樞紐二期 CaDAnCe-101 達主要終點、預計 2027 年年中送件，另有三期 NCT06846671（250 人）；Astellas setidegrasib 三期 NCT07409272 預計收 614 人。","安宏生醫 AH-001 外用 AR 降解藥一期（NCT06927960，64 人）已完成，主攻雄性禿；開拓藥業 GT20029 中國二期 180 人已於 2024-06-30 完成。"],"facts":[],"sections":["三句看懂","關鍵數字（附來源）","01｜降解藥不是把蛋白關掉，是把它丟進回收桶","02｜第一個上市藥教了一課：降解不等於大藥","03｜亞洲的兩個三期，都選了標靶藥失效的地方","04｜台灣：安宏走外用，避開全身用藥的戰場","05｜下一棒看三件事","參考資料"],"references":[{"title":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","source":"U.S. FDA","date":"2026-05-01","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast"},{"title":"Arvinas Q3 2026 earnings release (Form 8-K","source":"Arvinas／SEC","date":"2026-11-03","url":"https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069101/q32026earningsrelease.htm"},{"title":"BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates","source":"BeOne Medicines","date":"2026-11-05","url":"https://www.biospace.com/press-releases/beone-medicines-announces-third-quarter-2026-financial-results-and-business-updates"},{"title":"Nurix Therapeutics to Present New and Updated Data of Bexobrutideg (NX-5948) at the 68th ASH Annual Meeting","source":"Nurix Therapeutics","date":"2026-11-05","url":"https://globenewswire.com/news-release/2026/11/05/3396262/0/en/nurix-therapeutics-to-present-new-and-updated-data-from-ongoing-phase-1a-1b-trial-of-bexobrutideg-nx-5948-in-relapsed-refractory-cll-sll-at-the-68th-ash-annual-meeting-and-expositi.html"},{"title":"Tacabrutideg vs investigator's choice in CLL/SLL (NCT06846671","source":"ClinicalTrials.gov","date":"2026-09-28","url":"https://clinicaltrials.gov/study/NCT06846671"},{"title":"Setidegrasib with mFOLFIRINOX or NALIRIFOX in pancreatic cancer (NCT07409272","source":"ClinicalTrials.gov","date":"2026-11-03","url":"https://clinicaltrials.gov/study/NCT07409272"},{"title":"AH-001 topical SAD/MAD study (NCT06927960","source":"ClinicalTrials.gov","date":"2025-12-19","url":"https://clinicaltrials.gov/study/NCT06927960"},{"title":"GT20029 solution in androgenetic alopecia (NCT06692465","source":"ClinicalTrials.gov","date":"2024-11-18","url":"https://clinicaltrials.gov/study/NCT06692465"},{"title":"Bexobrutideg (NX-5948) phase 3 (NCT07516093","source":"ClinicalTrials.gov","date":"2026-08-31","url":"https://clinicaltrials.gov/study/NCT07516093"},{"title":"BMS-986365 phase 3 (NCT06764485","source":"ClinicalTrials.gov","date":"2026-09-30","url":"https://clinicaltrials.gov/study/NCT06764485"},{"title":"HP518 phase 1/2 (NCT06155084","source":"ClinicalTrials.gov","date":"2025-12-22","url":"https://clinicaltrials.gov/study/NCT06155084"},{"title":"HRS-1358 phase 1/2 (NCT06555068","source":"ClinicalTrials.gov","date":"2026-10-22","url":"https://clinicaltrials.gov/study/NCT06555068"},{"title":"UBX-303061 phase 1 (NCT06590961","source":"ClinicalTrials.gov","date":"2026-10-21","url":"https://clinicaltrials.gov/study/NCT06590961"},{"title":"BGB-45035 phase 2 (NCT07100938","source":"ClinicalTrials.gov","date":"2026-05-28","url":"https://clinicaltrials.gov/study/NCT07100938"}],"images":[{"alt":"圖1｜降解藥怎麼把致病蛋白送進回收桶","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/figure-01.png"},{"alt":"圖2｜亞洲與全球降解藥，同一把尺比進度","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/figure-02.png"},{"alt":"圖3｜各國降解藥走到哪一期","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/figure-03.png"},{"alt":"圖4｜外用 AR 降解藥：安宏與開拓的進度對照","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-10）。降解藥全景：首個PROTAC乳癌藥上市，亞洲接棒。https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「Veppanu（vepdegestrant）於 2026-05-01 獲 FDA 核准，是第一個上市的 PROTAC」有哪些關鍵變化？","a":"Veppanu（vepdegestrant）於 2026-05-01 獲 FDA 核准，是第一個上市的 PROTAC；Arvinas 2026 年第三季營收僅 50 萬美元，全為 Rigel 權利金。"},{"q":"「BeOne 於 2026-11-05 宣布 tacabrutideg 樞紐二期 CaDAnCe-101 達主要終點、預計 2027 年年中送件，另有三期 NCT06846671（250 人）」有哪些關鍵變化？","a":"BeOne 於 2026-11-05 宣布 tacabrutideg 樞紐二期 CaDAnCe-101 達主要終點、預計 2027 年年中送件，另有三期 NCT06846671（250 人）；Astellas setidegrasib 三期 NCT07409272 預計收 614 人。"},{"q":"「安宏生醫 AH-001 外用 AR 降解藥一期（NCT06927960，64 人）已完成，主攻雄性禿」有哪些關鍵變化？","a":"安宏生醫 AH-001 外用 AR 降解藥一期（NCT06927960，64 人）已完成，主攻雄性禿；開拓藥業 GT20029 中國二期 180 人已於 2024-06-30 完成。"}]}